


TARGET-IORT radiotherapy during lumpectomy for breast cancer

The TARGET-A- a large international randomised clinical trial



Conclusion: Risk-adapted TARGIT-IORT during lumpectomy vs. whole breast radiotherapy


- ✓ Comparable long-term breast cancer control, even when additional EBRT is not given
- ✓ Prognosis after the rare local recurrence remains excellent, unlike after EBRT
- ✓ Fewer deaths from cardiovascular causes, lung problems and other cancers
- ✓ Improved overall survival (by 4.5% at 12 years) if grade 1 or 2, no detriment if grade 3
- ✓ Less pain, less travel, less CO₂ emissions, and less cost
- ✓ Superior cosmetic outcome, improved quality of life, great patient convenience.

- Worldwide adoption in >260 centres in 35 countries
- Included in national and international guidelines
- Over 50,000 patients treated




TARGET-A trial : TARGIT-IORT vs whole breast radiotherapy (EBRT): long-term results




Comparable long-term breast cancer outcomes



Significantly fewer non-breast cancer deaths: by 4.4% at 12 years



Improved overall survival if grade 1 or 2 (n=1797)



Excellent prognosis if local rec.

